한글목차

세계 실로시빈 보조요법 시장의 미래는 군발두통, 불안장애, 정신질환 시장에서 기회가 있으며, 유망한 것으로 전망되고 있습니다. 세계 실로시빈 보조요법 시장은 2025-2031년까지 3.5%의 연평균 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 정신질환 유병률 증가, 합법화 및 규제 변화, 환각제 연구 및 개발에 대한 투자 증가 등입니다.

• Lucintel의 예측에 따르면, 천연 유래 실로시빈의 보급으로 인해 유형별로는 천연이 예측 기간 동안 가장 큰 부문을 유지할 것으로 예상됩니다.
• 용도별로는 정신의학 분야에서의 적용 범위가 넓기 때문에 정신질환이 가장 큰 부문을 차지할 것으로 예상됩니다.
• 지역별로는 북미가 규제 정비와 합법화로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

실로시빈 보조요법 시장의 새로운 동향

실로시빈 보조요법 시장은 연구 발전, 규제 변화, 대체 정신보건 치료에 대한 대중의 관심 증가로 인해 큰 변화를 겪고 있습니다. 이러한 추세는 실로시빈의 치료적 잠재력에 대한 인식이 높아지고 있다는 점과 정신건강 관리의 미래에 대한 의미를 강조하고 있습니다.

• 연구 및 임상 검사 증가 : 실로시빈의 치료 효과를 연구하는 임상 검사의 수는 최근 몇 년 동안 급격히 증가했습니다. 존스홉킨스 대학, 임페리얼 칼리지 런던, 캘리포니아 대학 등 주요 연구기관에서 우울증, PTSD, 중독 치료에 대한 실로시빈의 가능성을 시험하고 있습니다. 더 많은 연구가 유망한 결과를 보여줌에 따라 주류 정신건강 관리에서 실로시빈 보조요법의 수용도가 높아질 것으로 보입니다. 이러한 증거의 축적은 사이키델릭 치료의 법적 체계를 검토하는 정책 입안자들에게 영향을 미치고, 시장 확대를 촉진할 것으로 보입니다.
• 규제 변화와 합법화 : 실로시빈 보조요법 시장의 중요한 트렌드는 현재 진행 중인 규제 변화입니다. 미국에서는 오리건주가 2020년 실로시빈 요법을 합법화하기로 결정한 것이 선례가 되어 콜로라도, 워싱턴 등 다른 주에서도 유사한 조치에 관심을 보이고 있습니다. 또한, 캐나다와 유럽의 일부 국가에서는 환각요법에 대한 규제 프레임워크를 검토하고 있습니다. 법제화가 진행됨에 따라 시장에서는 실로시빈 보조요법에 대한 접근성이 확대되고, 임상 및 치료 현장에서의 채택이 증가할 것으로 보입니다.
• 정신건강 치료 프로그램과의 통합 : 실로시빈 보조요법은 종합적인 정신건강 치료 프로그램에 통합되고 있습니다. 치료사들은 실로시빈 세션과 심리치료를 결합하기 시작했으며, 이는 화합물의 치료 효과를 높이기 위한 모델입니다. 이러한 통합은 실로시빈의 심리적 효과가 전문가 상담과 함께 사용할 때 증폭된다는 증거에 의해 추진되고 있습니다. 정신건강 전문가들이 이 모델을 모색함에 따라, 특히 PTSD 및 치료 저항성 우울증과 같은 복잡한 정신건강 문제를 치료하는 데 있어 실로시빈 보조요법에 대한 수요가 크게 증가할 수 있습니다.
• 환각제에 대한 사회적, 문화적 변화 : 실로시빈을 포함한 환각제를 정신질환에 대한 효과적인 치료 옵션으로 개방하는 문화적 변화가 일어나고 있습니다. 언론 보도, 다큐멘터리, 서적은 치료 목적으로 환각제 사용을 정상화하는 데 중요한 역할을 하고 있습니다. 이러한 사회적 인식의 변화는 특히 대체치료에 관대한 젊은 세대를 중심으로 가속화되고 있습니다. 사회적 수용이 진행됨에 따라 환각 보조요법에 대한 수요는 증가할 것이며, 임상 현장뿐만 아니라 더 많은 사람들에게 보급될 것으로 예상됩니다.
• 사이키델릭 치료 제공자 확대 : 실로시빈 보조요법에 대한 관심이 높아지면서 민간 클리닉, 연구기관, 전문 웰니스 센터 등 새로운 치료 제공자가 등장했습니다. 이들은 임상과 수련회 모두에서 실로시빈 요법을 제공하며, 환자 맞춤형 경험을 제공하고 있습니다. 사이키델릭 보조요법의 가용성이 증가함에 따라, 특히 보험 적용과 규제가 발전함에 따라 치료는 더욱 친숙해지고 있습니다. 시장에서는 1:1 치료부터 그룹 세션, 리트릿 스타일 체험까지 서비스의 다양화가 진행될 것으로 보입니다.

실로시빈 보조요법의 새로운 트렌드는 접근성 확대, 연구 증가, 환각제에 대한 대중의 인식 변화 등을 통해 시장을 재편하고 있습니다. 임상 검사의 증가, 규제 변화, 광범위한 정신건강 치료 프로그램에 실로시빈의 통합으로 실로시빈 보조요법은 전 세계적으로 받아들여질 것으로 예상됩니다. 이러한 추세가 지속된다면 시장은 빠르게 성장하고, 정신건강 문제에 대한 대체 요법을 찾는 환자들이 늘어나면서 이 분야에 대한 혁신과 투자가 더욱 촉진될 것입니다.

실로시빈 보조요법 시장의 최근 동향

세계 실로시빈 보조요법 시장은 성장을 촉진하고 정신건강 치료의 상황을 변화시키는 몇 가지 주요 발전을 겪고 있습니다. 이러한 발전은 기술 발전, 규제 변화, 실로시빈의 치료 가능성에 대한 연구 증가로 인해 형성되고 있습니다.

• 규제 당국의 승인과 합법화 가장 중요한 발전 중 하나는 치료용 실로시빈의 합법화를 향한 움직임입니다. 2020년, 오레곤주가 미국 최초로 치료용 실로시빈을 합법화했고, 다른 주에서도 비슷한 조치를 검토하고 있습니다. 이러한 규제 변화로 다른 국가와 지역도 따라갈 수 있는 길이 열리고, 실로시빈 보조요법에 대한 접근성이 확대될 것으로 기대됩니다.
• FDA의 획기적 치료 지정 : 미국에서는 FDA가 우울증 치료제로 실로시빈을 획기적 치료제로 지정했습니다. 이번 지정을 통해 실로시빈을 이용한 치료법 개발이 가속화되고, 임상시험이 신속히 진행되어 궁극적으로 FDA의 주요 의료 현장에서의 사용 승인으로 이어질 것으로 기대됩니다.
• 실로시빈 연구에 대한 투자 증가 : 실로시빈 연구에 대한 투자가 증가하고 있으며, 일부 생명공학 기업 및 연구기관은 실로시빈이 정신질환에 미치는 영향에 대한 연구에 자원을 투입하고 있습니다. 존스홉킨스 대학, 임페리얼 칼리지 런던 등 주요 연구기관들이 이러한 연구의 최전선에 서 있습니다. 실로시빈의 효능을 뒷받침하는 과학적 증거가 계속 증가함에 따라 더 많은 자금과 자원이 시장에 유입될 것으로 예상됩니다.
• 세계 임상시험 확대 : 실로시빈의 임상시험은 전 세계적으로 확대되고 있으며, 유럽, 캐나다, 호주의 연구기관들이 치료 효과를 조사하는 노력에 참여하고 있습니다. 이러한 국제적인 확장은 발견의 속도를 가속화할 뿐만 아니라 보다 협력적인 세계 연구 환경을 촉진하여 규제 당국의 승인을 앞당기고 실로시빈 요법이 널리 채택될 가능성이 높습니다.
• 사이키델릭 기업과 의료 서비스 제공자의 파트너십 : 사이키델릭 요법을 제공하는 기업과 기존 의료 서비스 제공자와의 전략적 파트너십이 증가하고 있습니다. 이러한 협력 관계는 실로시빈 치료의 주류 의료 시스템으로의 통합을 촉진할 수 있습니다. 이러한 파트너십이 확대되면 임상 현장에서 실로시빈 보조요법을 제공할 수 있는 인프라가 구축되어 더 많은 환자들이 이 유망한 치료법을 이용할 수 있게 될 것으로 기대됩니다.

실로시빈 보조요법 시장의 최근 동향은 사이키델릭 보조요법의 광범위한 수용과 채택을 향한 큰 진전을 보이고 있습니다. 규제 변화, 연구 투자 증가, 임상 검사 확대 등으로 정신질환의 주류 치료제로서 실로시빈의 개발이 가속화되고 있습니다. 이러한 발전으로 인해 시장은 빠르게 성장하고 환자, 의료 서비스 제공자 및 투자자에게 새로운 기회를 제공할 것입니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 산업 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 실로시빈 보조요법 시장(유형별)

• 개요
• 유형별 매력 분석
• 천연 : 동향과 예측(2019-2031년)
• 합성 : 동향과 예측(2019-2031년)

제5장 용도별 실로시빈 보조요법 시장

• 개요
• 용도별 매력 분석
• 군발성 두통 : 동향과 예측(2019-2031년)
• 불안장애 : 동향과 예측(2019-2031년)
• 정신질환 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역별 실로시빈 보조요법 시장

제7장 북미의 실로시빈 보조요법 시장

• 개요
• 미국의 실로시빈 보조요법 시장
• 멕시코의 실로시빈 보조요법 시장
• 캐나다의 실로시빈 보조요법 시장

제8장 유럽의 실로시빈 보조요법 시장

• 개요
• 독일의 실로시빈 보조요법 시장
• 프랑스의 실로시빈 보조요법 시장
• 스페인의 실로시빈 보조요법 시장
• 이탈리아의 실로시빈 보조요법 시장
• 영국의 실로시빈 보조요법 시장

제9장 아시아태평양의 실로시빈 보조요법 시장

• 개요
• 일본의 실로시빈 보조요법 시장
• 인도의 실로시빈 보조요법 시장
• 중국의 실로시빈 보조요법 시장
• 한국의 실로시빈 보조요법 시장
• 인도네시아의 실로시빈 보조요법 시장

제10장 기타 지역의 실로시빈 보조요법 시장

• 개요
• 중동의 실로시빈 보조요법 시장
• 남미의 실로시빈 보조요법 시장
• 아프리카의 실로시빈 보조요법 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형에 의한 성장 기회
  • 용도에 의한 성장 기회
• 세계의 실로시빈 보조요법 시장의 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증과 라이선싱
  • 합병, 인수, 계약, 제휴, 합작투자

제13장 밸류체인 전체에 걸친 주요 기업 개요

• 경쟁 분석
• MindMed
• Compass Pathways
• ATAI Life Sciences
• Field Trip
• DemeRx

제14장 부록

• 그림목차
• 표목차
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• 당사에 대해
• 문의처

영문목차

The future of the global psilocybin assisted therapy market looks promising with opportunities in the cluster headaches, anxiety disorders and psychiatric disorders markets. The global psilocybin assisted therapy market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are rising prevalence of mental health disorders, growing legalization and regulatory shifts, and increased investment in psychedelic research and development.

• Lucintel forecasts that, within the type category, natural will remain larger segment over the forecast period due to prevalence of naturally occurring psilocybin.
• Within the application category, psychiatric disorders will remain the largest segment due to wider range of applications in psychiatry.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to regulatory developments and legalization.

Emerging Trends in the Psilocybin Assisted Therapy Market

The psilocybin assisted therapy market is undergoing significant changes, driven by evolving research, regulatory shifts, and increased public interest in alternative mental health treatments. These trends highlight the growing recognition of psilocybin's therapeutic potential and its implications for the future of mental health care.

• Growing Research and Clinical Trials: The number of clinical trials investigating the therapeutic benefits of psilocybin has dramatically increased in recent years. Major research institutions such as Johns Hopkins University, Imperial College London, and the University of California are conducting trials on psilocybin's potential to treat depression, PTSD, and addiction. As more studies demonstrate promising results, the acceptance of psilocybin assisted therapy in mainstream mental healthcare is likely to rise. This growing body of evidence will likely influence policymakers to consider legal frameworks for psychedelic therapy, thereby boosting market expansion.
• Regulatory Changes and Legalization: A significant trend in the psilocybin assisted therapy market is the ongoing shift in regulations. In the United States, Oregon's 2020 decision to legalize psilocybin therapy set a precedent, with other states such as Colorado and Washington showing interest in similar measures. Additionally, Canada and some European countries are considering regulatory frameworks for psychedelic therapies. As the legal landscape evolves, the market will see broader access to psilocybin-assisted therapies, leading to wider adoption in clinical and therapeutic settings.
• Integration with Mental Health Treatment Programs: Psilocybin-assisted therapy is increasingly being integrated into comprehensive mental health treatment programs. Therapists are beginning to combine psilocybin sessions with psychotherapy, a model that aims to enhance the therapeutic effects of the compound. This integration is driven by evidence suggesting that psilocybin's psychological benefits are amplified when used in conjunction with professional counseling. As mental health professionals explore this model, the demand for psilocybin assisted therapy could significantly increase, particularly in the treatment of complex mental health issues like PTSD and treatment-resistant depression.
• Public and Cultural Shifts Toward Psychedelics: There is a growing cultural shift toward openness about psychedelics, including psilocybin, as viable treatment options for mental health disorders. Media coverage, documentaries, and books have played a crucial role in normalizing the use of psychedelics for therapeutic purposes. This shift in public perception is accelerating, particularly among younger generations who are more open to alternative treatments. As societal acceptance grows, demand for psilocybin assisted therapy is expected to increase, expanding its reach to a wider audience beyond clinical settings.
• Expansion of Psychedelic Therapy Providers: The growing interest in psilocybin assisted therapy has led to the emergence of new therapy providers, including private clinics, research organizations, and specialized wellness centers. These providers are offering psilocybin therapy in both clinical and retreat settings, providing tailored experiences for patients. The increasing availability of psychedelic-assisted therapies is making treatment more accessible, especially as insurance coverage and regulations evolve. The market will see greater diversification in service offerings, ranging from one-on-one therapy to group sessions and retreat-style experiences.

The emerging trends in psilocybin assisted therapy are reshaping the market by expanding access, increasing research, and transforming public perceptions of psychedelics. Growing clinical trials, regulatory changes, and the integration of psilocybin into broader mental health treatment programs are expected to lead to greater acceptance of psilocybin assisted therapy worldwide. As these trends continue, the market is set to experience rapid expansion, with more patients seeking alternative therapies for mental health challenges, which will drive further innovation and investment in the sector.

Recent Developments in the Psilocybin Assisted Therapy Market

The global psilocybin assisted therapy market is experiencing several key developments that are driving growth and transforming the landscape of mental health treatment. These developments are shaped by technological advancements, regulatory changes, and growing research into the therapeutic potential of psilocybin.

• Regulatory Approvals and Legalization: One of the most significant developments is the move toward legalizing psilocybin for therapeutic use. In 2020, Oregon became the first state in the U.S. to legalize psilocybin for therapeutic use, with other states considering similar measures. This regulatory shift is expected to pave the way for other countries and regions to follow suit, expanding access to psilocybin assisted therapy.
• Breakthrough Therapy Designation by the FDA: In the U.S., the FDA granted breakthrough therapy designation to psilocybin for the treatment of depression, a key milestone that signals increased recognition of its therapeutic potential. This designation is accelerating the development of psilocybin-based treatments and is expected to expedite clinical trials, ultimately leading to FDA approval for its use in mainstream medical practices.
• Increased Investment in Psilocybin Research: Investment in psilocybin research is growing, with several biotech companies and research institutions dedicating resources to the study of psilocybin's effects on mental health disorders. Major research organizations like Johns Hopkins University and Imperial College London are at the forefront of these studies. As the body of scientific evidence supporting psilocybin's efficacy continues to grow, more funding and resources are expected to flow into the market.
• Global Expansion of Clinical Trials: Clinical trials for psilocybin are expanding globally, with research institutions in Europe, Canada, and Australia joining the effort to investigate its therapeutic benefits. This international expansion is not only accelerating the pace of discovery but also fostering a more collaborative global research environment, which is likely to result in faster regulatory approvals and broader adoption of psilocybin therapy.
• Partnerships Between Psychedelic Companies and Healthcare Providers: Strategic partnerships between psychedelic therapy companies and traditional healthcare providers are on the rise. These collaborations are facilitating the integration of psilocybin therapy into mainstream healthcare systems. As these partnerships grow, they will help create infrastructure for providing psilocybin assisted therapy in clinical settings, increasing access to this promising treatment for a broader patient population.

The recent developments in the psilocybin assisted therapy market are driving significant progress toward the widespread acceptance and adoption of psychedelic-assisted therapies. Regulatory changes, increased investment in research, and the expansion of clinical trials are accelerating the development of psilocybin as a mainstream treatment for mental health disorders. As these developments unfold, the market is poised for rapid growth, offering new opportunities for patients, healthcare providers, and investors alike.

Strategic Growth Opportunities in the Psilocybin Assisted Therapy Market

The global psilocybin assisted therapy market is evolving rapidly, driven by increasing research into the therapeutic benefits of psilocybin for mental health conditions like depression, PTSD, and anxiety. Psilocybin, a naturally occurring psychedelic compound, is gaining recognition as a potential game-changer in the mental health treatment landscape. As the regulatory environment shifts and more clinical trials validate its benefits, numerous growth opportunities are emerging in key applications. These opportunities are opening up new avenues for the industry, providing a path toward the widespread adoption of psilocybin as a mainstream treatment for various psychological conditions.

• Treatment of Depression: One of the most significant growth opportunities for psilocybin assisted therapy is in the treatment of depression, particularly treatment-resistant depression (TRD). Traditional antidepressants often fail to provide relief for a substantial portion of patients. Psilocybin has shown promise in clinical trials as an effective alternative for TRD, with studies indicating that it can provide long-lasting improvements in mood and emotional well-being. As research continues and regulatory bodies, like the FDA, grant breakthrough therapy designations, psilocybin assisted therapy for depression could become a mainstream option for patients seeking alternatives to conventional antidepressants, creating a new market segment.
• PTSD and Trauma Recovery: Another key growth opportunity lies in psilocybin assisted therapy for PTSD and trauma recovery. Clinical trials and anecdotal evidence have demonstrated that psilocybin can help individuals process traumatic memories, reduce emotional numbing, and alleviate symptoms of PTSD. As mental health professionals increasingly recognize the potential of psychedelics for trauma recovery, psilocybin assisted therapy is likely to be integrated into treatment protocols for PTSD, particularly in military veterans, survivors of sexual assault, and others suffering from trauma. The growing demand for innovative PTSD treatments, alongside promising research, positions psilocybin assisted therapy as a critical tool in this space.
• Addiction Treatment: Psilocybin-assisted therapy also holds promise as a treatment for addiction, particularly alcohol and tobacco use disorders. Research has shown that psilocybin can help individuals break free from addictive behaviors by promoting new perspectives and offering profound emotional and psychological insights. The ability of psilocybin to create lasting behavioral changes, combined with its potential to reduce cravings and anxiety, presents a major growth opportunity for the market. As addiction treatment centers begin to explore and implement psilocybin-based therapies, the demand for these services is expected to grow, creating a new niche for psilocybin therapy within the addiction recovery space.
• Anxiety and End-of-Life Care: Psilocybin-assisted therapy is also showing promise in the treatment of anxiety, particularly for patients facing life-threatening illnesses. Studies have found that psilocybin can reduce anxiety and existential distress in patients with terminal cancer, helping them come to terms with their mortality. As the aging population grows, the demand for effective anxiety and end-of-life care is expected to rise. Psilocybin's ability to facilitate a sense of peace, connectedness, and emotional clarity makes it an increasingly valuable tool in palliative care, offering significant growth potential for psilocybin assisted therapy in the healthcare sector.
• Integration into Mental Health Wellness Programs: As societal acceptance of psychedelic therapies increases, psilocybin assisted therapy is likely to become part of broader mental health and wellness programs. Wellness centers, retreat organizations, and private therapy practices are beginning to explore psilocybin as a tool for improving emotional well-being, fostering self-awareness, and promoting personal growth. Integrating psilocybin into these wellness programs, alongside traditional therapeutic practices like talk therapy, offers a new avenue for growth in the market. This trend could see psilocybin therapy expand beyond clinical settings and into the broader wellness and lifestyle sectors.

These strategic growth opportunities demonstrate the diverse potential applications of psilocybin assisted therapy across various sectors, including mental health, addiction treatment, and wellness. As research continues to validate the therapeutic benefits of psilocybin, its integration into clinical and wellness settings is poised to accelerate. The ongoing regulatory developments and cultural shifts toward the acceptance of psychedelics are further driving the market forward. Together, these opportunities will play a crucial role in shaping the future of psilocybin assisted therapy, making it a mainstream treatment option for a range of mental health conditions.

Psilocybin Assisted Therapy Market Driver and Challenges

The global psilocybin assisted therapy market is shaped by a combination of technological, economic, and regulatory factors. These drivers and challenges will determine the pace at which psilocybin can transition from research to mainstream medical use. Understanding these forces is essential for stakeholders, including pharmaceutical companies, healthcare providers, and policymakers, to navigate the evolving landscape of psychedelic-assisted therapies.

The factors responsible for driving the psilocybin assisted therapy market include:

1. Increasing Clinical Evidence Supporting Psilocybin's Efficacy: One of the primary drivers behind the market's growth is the growing body of clinical evidence that supports the effectiveness of psilocybin for treating various mental health conditions, including depression, PTSD, and addiction. The results from studies conducted by leading research institutions, such as Johns Hopkins University and Imperial College London, show that psilocybin has therapeutic potential for individuals who do not respond to conventional treatments. As these studies continue to yield positive results, more healthcare providers will be likely to adopt psilocybin assisted therapy, expanding its use in clinical practice.

2. Regulatory Shifts Toward Legalization: Regulatory changes are a critical factor driving the expansion of the psilocybin assisted therapy market. In recent years, there has been a noticeable shift in the regulatory landscape, particularly in the United States, with states like Oregon and Colorado legalizing psilocybin for therapeutic use. Additionally, the FDA has granted psilocybin breakthrough therapy status for depression, which accelerates the approval process. As more governments explore the potential benefits of psilocybin in treating mental health conditions, the regulatory environment will continue to evolve, facilitating broader access to psilocybin assisted therapy.

3. Societal Acceptance and Cultural Shift: As societal attitudes toward psychedelics continue to change, there is growing cultural acceptance of psilocybin-assisted therapies. Public figures, documentaries, and media coverage have played a significant role in normalizing the conversation around psychedelics. This cultural shift has led to an increased willingness among patients to explore alternative treatments for mental health issues. With more people seeking non-traditional therapies, psilocybin assisted therapy is positioned to meet this demand, providing a new therapeutic option for individuals who are open to innovative treatments.

4. Growing Mental Health Crisis: The global mental health crisis, exacerbated by factors such as the COVID-19 pandemic and rising stress levels, has created an urgent need for effective mental health treatments. Psilocybin-assisted therapy has emerged as a potential solution for addressing issues such as depression, anxiety, and PTSD, conditions that are often difficult to treat with conventional medications. As the demand for alternative therapies grows, psilocybin offers a new avenue for those seeking relief from chronic mental health conditions, driving the market's expansion.

5. Increasing Investment in Psychedelic Research and Startups: The increasing investment in psychedelic research and the rise of psychedelic startups are also major drivers in the growth of the psilocybin assisted therapy market. Investors are drawn to the potential of psychedelics as therapeutic agents, and the growing number of companies focused on psilocybin research and development is accelerating progress. With more funding, psilocybin therapy will be able to move through clinical trials faster and reach the market sooner, contributing to its wider adoption.

Challenges in the psilocybin assisted therapy market are:

1. Regulatory Hurdles and Legalization Delays: Despite the progress made in certain regions, psilocybin remains illegal in many countries. Regulatory challenges are a significant barrier to widespread adoption, as the legal status of psilocybin affects its availability and research. In regions where psilocybin remains prohibited, companies and researchers face difficulties conducting studies, limiting the overall growth potential of the market.

2. Stigma and Misunderstanding of Psychedelics: The stigma surrounding psychedelics, including psilocybin, remains a significant challenge. Public misconceptions about the safety and efficacy of psilocybin can hinder its acceptance as a legitimate therapeutic option. Changing public perception and overcoming historical biases toward psychedelics will require education, advocacy, and continued positive research findings.

3. Shortage of Trained Therapists: As psilocybin therapy expands, there will be an increasing need for trained therapists who are equipped to guide patients through the psilocybin-assisted treatment process. Currently, there is a shortage of mental health professionals with the specialized skills needed to administer psilocybin therapy safely. The development of training programs and certification standards for psilocybin assisted therapy will be crucial for the market's growth.

The drivers of the psilocybin assisted therapy market, including increasing clinical evidence, regulatory shifts, and growing societal acceptance, are pushing the market toward broader adoption. However, challenges such as regulatory hurdles, stigma, and the shortage of trained therapists remain. As the market continues to evolve, overcoming these challenges will be crucial to ensuring that psilocybin assisted therapy can achieve its full potential as a mainstream treatment for mental health disorders.

List of Psilocybin Assisted Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies psilocybin assisted therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the psilocybin assisted therapy companies profiled in this report include-

• MindMed
• Compass Pathways
• ATAI Life Sciences
• Field Trip
• DemeRx

Psilocybin Assisted Therapy Market by Segment

The study includes a forecast for the global psilocybin assisted therapy market by type, application, and region.

Psilocybin Assisted Therapy Market by Type [Value from 2019 to 2031]:

• Natural
• Synthetic

Psilocybin Assisted Therapy Market by Application [Value from 2019 to 2031]:

• Cluster Headaches
• Anxiety Disorders
• Psychiatric Disorders

Psilocybin Assisted Therapy Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Psilocybin Assisted Therapy Market

The global psilocybin assisted therapy market has witnessed significant advancements in recent years, as increasing research into the therapeutic benefits of psilocybin for mental health disorders has gained momentum. Psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has shown promise in treating conditions such as depression, PTSD, and anxiety. This growing interest in psychedelic-assisted therapies has led to notable developments in key markets such as the United States, China, Germany, India, and Japan. Various countries are exploring the potential of psilocybin for medical use, with evolving regulatory landscapes and breakthroughs in clinical trials contributing to the market's growth.

• United States: The United States has become a leading market for psilocybin assisted therapy, driven by significant advances in both research and regulatory changes. In 2020, Oregon became the first state to legalize psilocybin for therapeutic use, a milestone that has encouraged other states to follow suit. Clinical trials are underway, particularly by organizations such as Johns Hopkins University and MAPS (Multidisciplinary Association for Psychedelic Studies), exploring psilocybin's efficacy in treating PTSD, depression, and addiction. The FDA has granted breakthrough therapy designation to psilocybin for depression, signaling increasing recognition of its therapeutic potential.
• China: In China, psilocybin research is still in its early stages, but there is growing interest in the therapeutic use of psychedelics, including psilocybin. Although psilocybin remains illegal for recreational use, the Chinese government has recognized the potential benefits of psychedelics for treating mental health disorders. Research institutions and biotech companies are increasingly focused on exploring the medical use of psychedelics. While regulatory hurdles remain, growing global interest and the success of clinical trials in other regions could lead to a shift in policy in the coming years, potentially opening the door to psilocybin assisted therapy.
• Germany: Germany is one of the leaders in Europe when it comes to psilocybin research and the potential for legalizing psychedelic-assisted therapies. The country has a strong pharmaceutical and research infrastructure that has supported the growth of clinical trials investigating the use of psilocybin for mental health disorders. German researchers are actively exploring psilocybin's potential for treating depression, anxiety, and PTSD. The government has taken steps toward supporting the medical use of psychedelics, with regulations evolving to potentially allow psilocybin for therapeutic purposes, especially as scientific evidence continues to demonstrate its effectiveness in clinical settings.
• India: India's psilocybin assisted therapy market is still in its infancy, as the country's regulatory environment remains restrictive toward psychedelic substances. However, the increasing global interest in psychedelic research has sparked some discussions within India's scientific community regarding the potential for psilocybin to address mental health issues like depression, addiction, and anxiety. Clinical research is limited, but local organizations are starting to explore partnerships with international firms for trials. Public perception remains cautious, and the path toward legalizing psilocybin assisted therapy in India faces significant regulatory and cultural challenges.
• Japan: Japan has also seen some interest in psilocybin assisted therapy, although it is far behind the United States and Europe in this regard. Psilocybin remains illegal in Japan, but ongoing research into the medical use of psychedelics could potentially shift the regulatory landscape. Japanese researchers have started to examine the compound's effects on mental health, especially depression and anxiety, in controlled settings. The government's approach toward drug regulation is cautious, but the growing body of research in other countries, as well as positive clinical results, may prompt Japan to reconsider its stance on psilocybin assisted therapy in the future.

Features of the Global Psilocybin Assisted Therapy Market

• Market Size Estimates: Psilocybin assisted therapy market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Psilocybin assisted therapy market size by type, application, and region in terms of value ($B).
• Regional Analysis: Psilocybin assisted therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the psilocybin assisted therapy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the psilocybin assisted therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the psilocybin assisted therapy market by type (natural and synthetic), application (cluster headaches, anxiety disorders, and psychiatric disorders), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Psilocybin Assisted Therapy Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Natural: Trends and Forecast (2019-2031)
• 4.4 Synthetic: Trends and Forecast (2019-2031)

5. Global Psilocybin Assisted Therapy Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Cluster Headaches: Trends and Forecast (2019-2031)
• 5.4 Anxiety Disorders: Trends and Forecast (2019-2031)
• 5.5 Psychiatric Disorders: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Psilocybin Assisted Therapy Market by Region

7. North American Psilocybin Assisted Therapy Market

• 7.1 Overview
• 7.4 United States Psilocybin Assisted Therapy Market
• 7.5 Mexican Psilocybin Assisted Therapy Market
• 7.6 Canadian Psilocybin Assisted Therapy Market

8. European Psilocybin Assisted Therapy Market

• 8.1 Overview
• 8.4 German Psilocybin Assisted Therapy Market
• 8.5 French Psilocybin Assisted Therapy Market
• 8.6 Spanish Psilocybin Assisted Therapy Market
• 8.7 Italian Psilocybin Assisted Therapy Market
• 8.8 United Kingdom Psilocybin Assisted Therapy Market

9. APAC Psilocybin Assisted Therapy Market

• 9.1 Overview
• 9.4 Japanese Psilocybin Assisted Therapy Market
• 9.5 Indian Psilocybin Assisted Therapy Market
• 9.6 Chinese Psilocybin Assisted Therapy Market
• 9.7 South Korean Psilocybin Assisted Therapy Market
• 9.8 Indonesian Psilocybin Assisted Therapy Market

10. ROW Psilocybin Assisted Therapy Market

• 10.1 Overview
• 10.4 Middle Eastern Psilocybin Assisted Therapy Market
• 10.5 South American Psilocybin Assisted Therapy Market
• 10.6 African Psilocybin Assisted Therapy Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Psilocybin Assisted Therapy Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 MindMed
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Compass Pathways
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 ATAI Life Sciences
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Field Trip
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 DemeRx
  • Company Overview
  • Psilocybin Assisted Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us